Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer

Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news